Explore CJC-1295 No DAC/Ipamorelin blend dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA calculator sessions.
The CJC-1295 No DAC/Ipamorelin combination is one of the most widely used GHRH/GHRP stacks in peptide research, requiring careful reconstitution of both peptides. This data shows the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select for this GH-stimulating peptide blend.
CJC-1295 No DAC + Ipamorelin is a deliberate two-peptide pairing that combines a short-acting GHRH analog with a selective GHRP, and the rationale traces to two separate strands of growth-hormone-axis research. The DAC — Drug Affinity Complex — is a chemical linker built into the original CJC-1295 molecule that binds to albumin (the most abundant protein circulating in the blood) immediately after injection, stretching the peptide's active life from about 30 minutes to roughly 7 to 8 days. That long residence creates a slow, continuous GH stimulus instead of the sharp natural pulses the pituitary normally produces — which is why protocols focused on pulsatile release deliberately use the No DAC form.
This blend pairs CJC-1295 without DAC (Mod GRF 1-29) with ipamorelin, and is one of the most-sourced growth-hormone-axis research combinations. It ships as a co-lyophilized powder reconstituted with bacteriostatic water before use.
CJC-1295 no-DAC stimulates the pituitary somatotrophs through the GHRH receptor while ipamorelin acts on the parallel ghrelin/GHS-R1a pathway. Used together the two peptides produce a synergistic, pulsatile GH release that preserves the body's natural circadian GH rhythm, in contrast to recombinant hGH which abolishes endogenous pulsatility.
Published research is limited to the parent peptides individually — a Phase 1 study of CJC-1295 no-DAC in healthy adults (Teichman et al., JCEM 2006) documented dose-dependent IGF-1 elevation, and ipamorelin was characterized for GH selectivity by Raun et al. (Eur J Endocrinol 1998). No published trials evaluate the combination as a fixed-ratio research blend.
CJC-1295 No DAC/Ipamorelin Blend has a reported half-life of ~30 min (CJC) and ~2 hr (Ipamorelin), and the dose intervals researchers model most often fall around once daily (before bed). Both components are short-acting — they work as a pulse rather than a steady-state level. The CJC-1295 (no DAC) component clears within an hour; Ipamorelin within a few hours. CJC-1295 No DAC/Ipamorelin Blend is a blend of CJC-1295 (no DAC) and Ipamorelin, so a reconstitution figure for it covers the combined vial contents rather than any single component. It is catalogued under Muscle Peptides on WPA.
8,574 CJC-1295 No DAC/Ipamorelin Blend reconstitution calculations have been logged by the WPA community. The most common dose entered is 250mcg (1,689 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (5,944 sessions). The most common dosing frequency is daily (7x/week) (1,000 logged protocols), followed by 5x/week (533).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.